Navigation Links
Licorice compound offers new cancer prevention strategy
Date:3/23/2009

A chemical component of licorice may offer a new approach to preventing colorectal cancer without the adverse side effects of other preventive therapies, Vanderbilt University Medical Center researchers report.

In the study published in the Journal of Clinical Investigation, Raymond Harris, M.D., Ming-Zhi Zhang, M.D., and colleagues show that inhibiting the enzyme 11β-hydroxysteroid dehydrogenase type 2 (11βHSD2) either by treatment with a natural compound found in licorice or by silencing the 11βHSD2 gene prevents colorectal cancer progression in mice predisposed to the disease.

Colorectal cancer is the second leading cause of cancer deaths in the United States. While prevention is the best approach for reducing colorectal cancer deaths, few medical strategies exist to prevent the disease.

One promising target for chemoprevention is the enzyme cyclooxygenase 2 (COX-2), which promotes colorectal cancer progression via the action of the enzyme's inflammatory products, the prostaglandins. Inhibiting this enzyme with non-steroidal anti-inflammatory drugs (NSAIDs) like ibuprofen or with selective COX-2 inhibitors like Vioxx or Celebrex reduces the number and size of colon polyps in mice and in patients with an inherited predisposition to colon cancer. However, both types of drugs cause serious adverse side effects that limit their utility for chemoprevention.

Harris and Zhang nephrologists who are also members of the Vanderbilt-Ingram Cancer Center have been investigating COX-2 regulation in the kidney. They previously found that inhibiting 11βHSD2 in the kidney suppresses COX-2 expression in that organ.

The colon is one of the only other organs (besides the kidney) with high expression of 11βHSD2, suggesting that this enzyme might play a role in colorectal cancer progression.

"Since studies here and elsewhere have shown the importance of COX-2 and colonic carcinogen
'/>"/>

Contact: Melissa Marino
melissa.marino@vanderbilt.edu
615-322-4747
Vanderbilt University Medical Center
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. Licorice extract provides new treatment option for canker sores
2. TV crime drama compound highlights immune cells misdeeds
3. The Texas Institute of Dermatology Team Finds Easy-to-Apply, Topical Drug Just as Good as Injectable Compound for a Disfigurating Skin Infection
4. Chili Pepper Compound Can Bring Pain Relief
5. Compounds Found to Protect Rabbits From Cerebral Palsy
6. Compounds that trigger beta cell replication identified by JDRF funded researchers
7. Stunning finding: Compounds protect against cerebral palsy
8. Blood pressure compound may benefit brain tumor patients
9. Australias Leading Oncology Drug Compounder Chooses RIVA System
10. AstraZeneca Licenses Novel Antidepressant Compounds Discovered by Mayo Clinic and Virginia Tech Collaboration
11. HPS Establishes Independent Website for its Patent-Pending Mood-Enhancing Compound Naturally Found in Sea Coral
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Stallergenes: Oralair: Very Positive 3-Year Results of the Long-Term Study 2Stallergenes: Oralair: Very Positive 3-Year Results of the Long-Term Study 3Stallergenes: Oralair: Very Positive 3-Year Results of the Long-Term Study 4Stallergenes: Oralair: Very Positive 3-Year Results of the Long-Term Study 5Hill-Rom Announces Appointment of James R. Giertz to Board of Directors 2The Epilepsy Research Foundation and Milken Family Foundation Announce Prestigious Translational Research Grants for Two Pioneering Epilepsy Therapies 2The Epilepsy Research Foundation and Milken Family Foundation Announce Prestigious Translational Research Grants for Two Pioneering Epilepsy Therapies 3The Epilepsy Research Foundation and Milken Family Foundation Announce Prestigious Translational Research Grants for Two Pioneering Epilepsy Therapies 4The Epilepsy Research Foundation and Milken Family Foundation Announce Prestigious Translational Research Grants for Two Pioneering Epilepsy Therapies 5CRF announces late breaking trials to be presented at TCT 2009 in San Francisco 54339 1CRF announces late breaking trials to be presented at TCT 2009 in San Francisco 54339 2CRF announces late breaking trials to be presented at TCT 2009 in San Francisco 54339 3National Cancer Institute names Emory to nationwide NCI chemical biology consortium 54337 1National Cancer Institute names Emory to nationwide NCI chemical biology consortium 54337 2National Cancer Institute names Emory to nationwide NCI chemical biology consortium 54337 3National Cancer Institute names Emory to nationwide NCI chemical biology consortium 54337 4Accera Announces Peer Reviewed Publication of the Results of its 90 Day Clinical Study of AC 1202 28Axona 28TM 29 29 in Mild to Moderate Alzheimers 13530 1Accera Announces Peer Reviewed Publication of the Results of its 90 Day Clinical Study of AC 1202 28Axona 28TM 29 29 in Mild to Moderate Alzheimers 13530 2Accera Announces Peer Reviewed Publication of the Results of its 90 Day Clinical Study of AC 1202 28Axona 28TM 29 29 in Mild to Moderate Alzheimers 13530 3